GSK challenges Meningococcal serogroup B mkt with Bexsero
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.07.18 05:40:02
가나다라
0
GSK releases Bexsero, which offers strength against the Meningococcal serogroup, following the release of Menveo
The proportion of meningococcal serogroup B in Korea increased to 78% recently...accounts for a large share of patients in Korea
GSK Korea emphasizes its joint marketing strategy for Menveo-Bexsero, rather than occupation of a specific vaccine market
GSK and Sanofi, the leading meningococcal vaccine companies in Korea, are set to face new competition with the approval of their next-generation vaccines.
GSK Korea plans to gain competitivity with Bexsero, which has strengths in protecting against serogroup B, which accounts for the largest share of meningococcal infections in Korea since 2010.
#1 GSK Korea held a press conference to celebrate the launch of Bexsero, the first meningococcal serogroup B vaccine in Korea, and discussed the current status of meningococcal B outbreaks and the effectiveness of its vaccine.
Meningococcal infections can cause invasive meningococcal infections, meningitis, and sepsis. Invasive menin
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)